FDA Approves New Manufacturing Process For Premarin Formulation
This article was originally published in The Pink Sheet Daily
Executive Summary
Improvements were made to the manufacturing process for 1.25 mg tablets and the inactive ingredients were changed, resulting in a more robust dissolution profile, Wyeth says. The company plans to seek approval of the new manufacturing process for other strengths of the hormone therapy.